Viright

ViRight is a biotechnology company dedicated to advancing gene therapy through the development of next-generation adeno-associated virus (AAV) vectors. The company utilizes a proprietary high-throughput AAV capsid evolution platform to engineer viral vectors with superior tissue specificity, reduced pre-existing immunity, and enhanced manufacturing yields. ViRight's research primarily targets the central nervous system (CNS), eye, and liver, aiming to provide more effective treatments for rare genetic diseases and complex chronic conditions. By optimizing the delivery vehicle, the company seeks to expand the therapeutic window and clinical utility of gene-based medicines. Headquartered in Suzhou, China, ViRight is led by experts in viral vector engineering and gene therapy development.